Avenue Therapeutics (NASDAQ:ATXI) Posts Quarterly Earnings Results, Misses Estimates By $5.38 EPS

Avenue Therapeutics (NASDAQ:ATXI) issued its earnings results on Friday. The company reported ($6.43) EPS for the quarter, missing the consensus estimate of ($1.05) by ($5.38), Zacks reports.

Avenue Therapeutics Price Performance

NASDAQ:ATXI traded up $0.02 during midday trading on Monday, reaching $2.49. 32,123 shares of the company traded hands, compared to its average volume of 67,814. Avenue Therapeutics has a twelve month low of $2.25 and a twelve month high of $78.75. The firm has a market capitalization of $2.34 million, a price-to-earnings ratio of -0.32 and a beta of -0.19. The company has a fifty day moving average price of $3.30 and a 200 day moving average price of $7.06.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.